首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1461274

流感疫苗市場，依疫苗類型，依效價，依給藥途徑，依年齡層，依技術，依配銷通路，依地理

Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography

出版日期: 2024年03月18日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年流感疫苗市值為83億美元，預計2031年將達到134.3億美元，2024年至2031年的年複合成長率（CAGR）為7.1%。

報告範圍		報告詳情
基準年：	2023年	2023/2024 年市場規模：	83億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率：	7.10%	2030/2031 價值預測：	134.3 億美元

2024 年依地區分類的流感疫苗市佔率 (%)

預計 2024 年全球流感疫苗市場價值為 83 億美元，預計在預測期內（2024-2031 年）複合年成長率為 7.1%。幾十年來，流感疫苗一直是預防保健的重要組成部分。流感病毒具有定期變異和進化的能力，因此需要每年開發更新的疫苗。這些疫苗可以增強人體對這些不斷變化的病毒的免疫反應。它們旨在針對三種或四種病毒株（取決於特定流感季節使用的疫苗類型）進行免疫，監測和其他科學研究已確定這些病毒株最有可能在任何特定地區即將到來的流感季節流行。由於人們對季節性疫苗接種的認知不斷增強、新技術的引入、醫療保健組織擴大疫苗接種指南以及全球政府的支持不斷增加，全球流感疫苗市場在過去幾年中穩步成長。

市場動態：

全球流感疫苗市場的成長是由多種因素推動的，例如流感盛行率的增加、國際衛生組織制定的疫苗接種指南的日益採用、疫苗接種意識的提高、新產品的推出、對重組技術疫苗的日益偏好以及地理範圍的擴大。然而，由於開發四價流感疫苗涉及高昂的研發成本、批准新疫苗的嚴格監管指南以及由於流感病毒株抗原漂移而產生的疫苗抗藥性，市場成長可能面臨課題。由於醫療基礎設施的改善和可支配收入的增加，市場參與者看到了新興國家的機會。製造商也致力於開發針對多種流感病毒株具有持久保護作用的通用流感疫苗。

研究的主要特點：

該報告對全球流感疫苗市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數介紹了全球流感疫苗市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球流感疫苗市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球流感疫苗市場的各種策略矩陣輕鬆做出決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地區
歐洲
德國
英國
法國
義大利
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
澳洲
韓國
東協
亞太地區其他地區
中東
海灣合作理事會
以色列
中東其他地區
非洲
南非
中非
北非

第 12 章：競爭格局

熱圖分析
市佔率分析
- CSL Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
- Solaris Vaccines

第 13 章：分析師觀點

命運之輪
分析師觀點
連貫的機會圖

第 14 章：參考文獻與研究方法

參考
研究方法論

簡介目錄

Product Code: CMI1705

The influenza vaccines market is estimated to be valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 8.30 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	7.10%	2030/2031 Value Projection:	US$ 13.43 Bn

Influenza Vaccines Market Share (%), By Region, 2024

Global influenza vaccines market is estimated to be valued at USD 8.30 BN in 2024 and is expected to exhibit a CAGR of 7.1% during the forecast period (2024-2031). Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.

Market Dynamics:

The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.

Key Features of the Study:

This report provides an in-depth analysis of the global influenza vaccines market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.

Market Segmentation

Vaccine Type:
- Inactivated
- Live Attenuated
Valency:
- Quadrivalent
- Trivalent
Route of Administration:
- Injection
- Nasal Spray
Age Group:
- Pediatrics
- Adults
Technology:
- Egg-Based Flu Vaccines
- Cell Culture-Based Flu Vaccines
- Recombinant Flu Vaccines
Distribution Channel:
- Public
- Private
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen Inc.
- Moderna Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- CSL
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Valency
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Influenza Vaccines Market- Impact of Coronavirus (COVID-19) Pandemic

Impact on Demand
Impact on Healthcare
Epidemiology

5. Global Influenza Vaccines Market, By Vaccine Type, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Influenza Vaccines Market, By Valency, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Trivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Influenza Vaccines Market, By Route of Administration, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Influenza Vaccines Market, By Age Group, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)

9. Global Influenza Vaccines Market, By Technology, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Egg-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Cell Culture-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Recombinant Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)

10. Global Influenza Vaccines Market, By Distribution Channel, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)

11. Global Influenza Vaccines Market, By Region, 2019 - 2031 (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031(%)
- Y-o-Y Growth Analysis, For Regions, 2019 - 2031
- Regional Trends
North America
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
U.S.
Canada
Latin America
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Region/Country, 2019 - 2031 (USD BN)
South Africa
Central Africa
North Africa

12. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- CSL Seqirus
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
- Solaris Vaccines